Feb 6, 2025
This suspension is one that has been hovering on the edge of unprofitability for a long time and has seen more concessions granted (32) in 2023 – 2024 that any other generic. Between Nov 2017 and Dec 2019 market prices averaged close to or below £4.00. This...
Jan 6, 2025
This product has seen its market price decay from around £13.00 in 2017 – 2020 to a low of £4.29 in September 2024. This may have pushed this combined product, complicated to make due to its combined and device characteristics, into unprofitability as it has...
Nov 15, 2024
With the number of concessions granted by DHSC in October at just 106, the lowest number since May 2022, we wondered if this was a signal of a reduction in the number of shortages or if it was just a blip? To try and understand this issue we needed to get some way of...
Oct 3, 2024
WaveData’s Head of Data, Natalie Fancourt, alerted us to the huge price spikes on Apixaban 5mg 56. Charles Joynson, WaveData MD, decided to investigate the longer term view of both the Generic and Brand. The 5mg 56 pack is the most commonly used of the six packs...
Jul 10, 2024
Twice before WaveData to have looked into this subject only to find there is no link between product value and the delay in the introduction of Category M. However, time moves on, so we thought we’d repeat the analysis, partly because of a recent client request, and...
Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
